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Mutations in the epithelial morphogen ectodyspla-
sin-A (EDA), a member of the tumor necrosis factor
(TNF) family, are responsible for the human disorder
X-linked hypohidrotic ectodermal dysplasia (XLHED)
characterized by impaired development of hair, eccrine
sweat glands, and teeth. EDA-A1 and EDA-A2 are two
splice variants of EDA, which bind distinct EDA-A1 and
X-linked EDA-A2 receptors. We identified a series of
novel EDA mutations in families with XLHED, allowing
the identification of the following three functionally im-
portant regions in EDA: a C-terminal TNF homology
domain, a collagen domain, and a furin protease recog-
nition sequence. Mutations in the TNF homology do-
main impair binding of both splice variants to their
receptors. Mutations in the collagen domain can inhibit
multimerization of the TNF homology region, whereas
those in the consensus furin recognition sequence pre-
vent proteolytic cleavage of EDA. Finally, a mutation
affecting an intron splice donor site is predicted to elim-
inate specifically the EDA-A1 but not the EDA-A2 splice
variant. Thus a proteolytically processed, oligomeric
form of EDA-A1 is required in vivo for proper
morphogenesis.
The ED1 gene encodes a protein, ectodysplasin-A (EDA),1
recently recognized to be a member of the tumor necrosis factor
(TNF) superfamily of ligands. Mutations within the ED1 gene
cause an X-linked recessive disorder, hypohidrotic or anhi-
drotic ectodermal dysplasia (ED1, XLHED) (Mendelian inher-
itance in man 305100), involving abnormal morphogenesis of
teeth, hair, and eccrine sweat glands. Various splice forms of
the ED1 transcript have been detected, but two isoforms dif-
fering only by two amino acids, EDA-A1 (391 aa) and EDA-A2
(389 aa), contain a TNF homology domain (1–3). EDA is a type
II transmembrane protein with a small N-terminal intracellu-
lar domain and a larger C-terminal extracellular domain con-
taining a (Gly-X-Y)19 collagen-like repeat with a single inter-
ruption and a C-terminal TNF homology domain (Fig. 1A). The
TNF homology domain is similar to other members of the TNF
family, consisting of 10 predicted anti-parallel b-sheets linked
by variable loops (Fig. 1A). TNF family ligands homotrimerize
to form a pear-shaped quaternary structure able to bind a
receptor molecule at each monomer-monomer interface (4, 5).
The closest EDA homologues in the TNF family are BAFF/
BLyS, APRIL, and TWEAK, although none of them contains
collagen-like repeats (6–9). All four ligands contain consensus
sequences for proteolytic cleavage by furin within their extra-
cellular domain. In the case of EDA, two overlapping consensus
sites are located between the transmembrane and the collagen-
like domains (Fig. 1A). EDA-A1, but not EDA-A2, has been
shown to specifically bind to EDAR, a member of the TNF
receptor superfamily that, like most members of the TNF re-
ceptor family, activates the NF-kB and c-Jun N-terminal ki-
nase pathways (3, 10). Mutations in DL (EDAR), the human
homologue of the murine downless locus, produce an identical
phenotype to loss of function of EDA (11, 12). XEDAR, another
member of the TNF receptor superfamily that also activates
the NF-kB pathway, binds EDA-A2 but not EDA-A1. Although
EDA-A1 and EDA-A2 are closely related splice variants, the
respective proteins appear to have different patterns of expres-
sion in mouse skin and hair follicles (3). Intracellular signals
elicited by EDA in vivo rely at least in part on the activation of
NF-kB, because a rare form of HED associated with immuno-
deficiency (HED-ID) correlates with mutations in NEMO/
IKK-g, an essential component of the NF-kB pathway (13).
In order to get insight into the structure-function relation-
ship of EDA, we identified 44 mutations (17 of which have not
been reported previously) in unrelated families with XLHED
and studied their effect on the properties of EDA in vitro. The
mutations clustered in three functionally important domains
as follows: a TNF homology domain necessary for receptor
binding, a bundle-forming collagen domain, and a cleavage site
for a furin protease. This indicates that the receptor binding
ability of EDA and also its oligomerization and proteolytic proc-
essing to a soluble form are critical events for its action in vivo.
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MATERIALS AND METHODS
Families Analyzed—Seventy apparently unrelated families with hy-
pohidrotic ectodermal dysplasia were identified by clinicians at various
centers and recruited into a research study approved by the institu-
tional review board of the Oregon Health Sciences University. Consent
was obtained for the use of clinical information, relevant family history,
and DNA samples. Family histories and clinical data were provided by
the clinical centers. A single individual was screened for mutations in
each family. Fifty affected males had the classical findings of hypodon-
tia, hypotrichosis and hyphidrosis (decreased amount of teeth, hair, and
sweat glands, respectively), whereas 20 carrier females were either
obligate carriers or had clear manifestations of the disorder. 38 of the
families had more than one affected individual (multiplex families),
whereas the remaining 32 cases were sporadic (simplex families). A
subset of the families had been analyzed previously and shown to have
no detectable mutations within exon 1 of ED1 (14).
Mutation Detection—The eight exons coding for EDA-A1 and
EDA-A2 were amplified by PCR from genomic DNA of patients and
controls using a Stratagene Robocycler with the primers and conditions
listed in Table I. Genomic DNA samples from controls and 15 known
mutations, previously detected by complete sequencing of the ED1
gene, were run as controls under the same conditions utilizing single-
stranded conformation polymorphism (SSCP) analysis (14). PCR frag-
ments from exons 1, 5, and 9 were digested to produce restriction
fragments in the 100–270-base pair range (Table I). All samples were
then denatured at 95 °C for 5 min, chilled on ice, and electrophoresed on
a 0.53 MDETM polyacrylamide gel (FMC Corp.) at room temperature
for SSCP analysis. Electrophoresis of all samples, except for those from
exon 1, was performed in 10% glycerol. DNA was visualized by silver
staining (14). Samples having abnormally migrating bands were re-
amplified from stock genomic DNA, purified by use of Geneclean (Bio
101), and sequenced on both strands by use of ABI end-terminator
chemistry on either a 373A or 377 automated sequencer. A previously
identified recurrent mutation, G4673 A (R156H) was not detectable by
SSCP using several sets of conditions. However, the mutation elimi-
nates a restriction site for Fnu4H1 (gc/ngc). Therefore, PCR fragments
from exon 3 with normally migrating bands on SSCP were digested
with Fnu4H1 and electrophoresed on a 3% agarose gel. Genomic DNA
from the mothers of individuals with confirmed mutations were also
sequenced. Sequence alignments were performed using a pairwise se-
quence alignment program.
Production of Recombinant Proteins—Cloning of ligands and recep-
tors in suitable vectors and expression of the recombinant proteins in
293T cells were performed essentially as described previously (15). The
source of cDNAs used in this study was as follows: mouse EDA-A1 (aa
245–391) and EDA-A2 (aa 245–389) were amplified by nested reverse
transcriptase-PCR from mouse lung and brain cDNAs, respectively
(using primer pair 59GGA TTC CAG GAA CAA CTG TTA TGG39 and
59CCT ACA CAC AGC AAG CAC CTT AGA G39 for the initial PCR). In
this region, the murine and human proteins are 100% identical. Full-
length cDNAs for hEDA and hEDAR have been described earlier (2, 12),
and XEDAR cDNA was from clone 5091511 (LifeSeqt Gold, Incyte
Genomics, Palo Alto, CA). The expression construct for XEDAR:Fc
carried a human immunoglobulin m chain signal sequence, the region
coding for amino acids 1–135 of XEDAR flanked by AatII and SalI sites,
and the Fc portion of human IgG1, in a modified PCR-3 expression
vector (Invitrogen). The extracellular domain of hEDAR (aa 1–183) was
cloned into the Fc fusion expression vector. Expression vectors for
various soluble forms of FLAG-tagged EDA were constructed in a vector
containing the signal peptide of hemagglutinin (see Fig. 1B) as follows:
EDA-A1 Glu245 (aa 245–391), EDA-A2 Glu245 (aa 245–389), EDA-A1
Ser160 (aa 160–391), and EDA-A1 Ser66 (aa 66–391). The following
point mutations were generated by PCR-based methods in both
EDA-A1 and EDA-A2 E245: H252L, Y343C (Y341C), A356D (A354D),
S374R (S372R), T378M (T376M) (mutations in parentheses refer to
EDA-A2 which lacks amino acids 307 and 308. For the sake of clarity,
the EDA-A1 mutant nomenclature will be used for both ligands.). The
following mutants were also constructed: EDA-A1 Ser66 R153C,
EDA-A1 Ser66 R156C, and EDA-A1 Ser66 D185–196. For the expression
vectors for EDA, FasL fusion proteins contained the hemagglutinin
signal peptide, a FLAG tag, the entire or truncated collagen domain of
EDA (aa Ser160–Arg244, aa Ser160–Arg244 D185–196, aa Ser160–Arg244
D218–223, aa Ser160–Arg244 G207R, aa Gly210–Arg244), and the TNF
homology domain of FasL (aa Glu139–Leu281 of hFasL). Finally, muta-
tions C86R and R87P were introduced in hEDAR:Fc. All constructs
were sequenced on both strands. CHO cells were transfected with
Polyfect reagent (Qiagen), according to the manufacturer’s instructions.
Cell Lines—HEK-233T cells were maintained in Dulbecco’s modified
Eagle’s medium and CHO dhfr2 cells in a-minimum essential medium
containing ribonucleosides and deoxyribonucleosides (Life Technolo-
gies, Inc.). Culture media were supplemented with 10% of heat-inacti-
vated fetal calf serum and antibiotics.
Deglycosylation—Denatured samples of EDA were submitted to deg-
lycosylation with peptide N-glycanase F for 16 h at 37 °C, following the
manufacturer’s recommendations (New England Biolabs).
Receptor Binding ELISA—The following steps were performed: (a)
coating with 5 mg/ml mouse anti-human IgG antibodies (Jackson Im-
munoResearch) in 50 mM carbonate buffer, pH 9.6; (b) incubation in
block buffer (PBS, 0.5% Tween 20, 4% skimmed milk); (c) incubation
with cell supernatants containing the indicated receptor:Fc fusion pro-
teins (20 ml supernatant in 100 ml of incubation buffer: PBS, 0.05%
Tween 20, 0.4% milk); (d) incubation with cell supernatants containing
the indicated FLAG ligands (20 ml of supernatant in 100 ml of incuba-
tion buffer); (e) incubation with 0.5 mg/ml biotinylated anti-FLAG M2
antibody (Sigma) in incubation buffer; (f) incubation with horseradish
peroxidase-coupled streptavidin (1/4000, Jackson ImmunoResearch) in
incubation buffer. Alternatively, steps d—f were replaced by an incu-
bation with horseradish peroxidase-coupled goat anti-human IgG. Four
washing steps with PBS 0.05% Tween 20 were performed between
incubations. 100 ml of ortho-phenylenediamine solution was added (Sig-
ma fast o-phenylenediamine dihydrochloride tablet sets, Sigma), and
the reaction was stopped by addition of 50 ml of 2 N HCl, and A490 nm was
taken.
Immunoprecipitations—FLAG ligands (about 100 ng in 100–400 ml
of cell supernatants) were added to 5 ml of M2-agarose affinity matrix
(Sigma). Receptors:Fc (about 500 ng in 100–400 ml of cell supernatants)
were mixed with FLAG ligands (about 100 ng) and 5 ml of protein
A-Sepharose. All samples were diluted to 1 ml with PBS and incubated
on a rotating wheel for 1 h at 4 °C. Beads were recovered in mini-
columns, washed with 23 400 ml of PBS, and eluted in 15 ml of 0.1 M
citrate/NaOH, pH 2.7. Neutralized eluates were prepared for Western
blot analysis under reducing conditions. Membrane were probed with
anti-FLAG M2 antibody or rabbit anti-EDA antibodies and subse-
quently reprobed with goat anti-human IgG antibodies.
Gel Permeation Chromatography—200 ml of transfected cell super-
natants mixed with internal standards (40 mg of catalase and 100 mg of
ovalbumin) was applied onto a Superdex-200 column and eluted in PBS
at 0.5 ml/min. Fractions of 700 ml were collected and supplemented with
40 mg of lysozyme. Proteins were recovered by precipitation in chloro-
form/methanol and analyzed by Western blot.
Cytotoxic Assay—Cytotoxic assays in the presence or absence of 1
mg/ml of M2 antibody were performed as described previously, using the
FasL-sensitive Jurkat cell line and measuring cell viability after 16 h
with the phenazine methosulfate/3-[4, 5-dimethylthiazol-2-yl]-5-[3-car-
boxymethoxyphenyl]-2-[4-sulfonyl]-2H-tetrazolium test (16).
N-terminal Sequence Determination—EDA Ser66 and EDA Ser66
R153C were expressed in 293T cells. Supernatants (10 ml) were immu-
noprecipitated with 10 mg of EDAR:Fc and 20 ml of protein A-Sepharose
as described above. Samples were reduced, blotted onto polyvinylidene
difluoride membranes, and stained with Ponceau S. Bands of interest
were submitted to automated Edman degradation using an ABI 120A
gas phase sequencer coupled to an ABI 120A analyzer equipped with a
phenylthiohydantoin C18 2.1 3 250 mm column. Data were analyzed
using ABI 610 software.
Anti-EDA Antibodies—Anti-EDA rabbit anti-serum (AL166) was ob-
tained by custom rabbit immunization using purified FLAG-EDA E245
as immunogen (Eurogentech, Seraing, Belgium). Serum was used at a
dilution of 1/500 for Western blotting.
RESULTS
Identification of Mutations in HED—Twenty five different
mutations of the ED1 gene were detected in 44 of the 70
unrelated families analyzed (63%), and 9 were demonstrated to
have occurred de novo (footnoted in Table II). As 17 of these
mutations had not been described previously, the number of
different ED1 mutations identified to date in XLHED patients
totals 53 (Table II). Analysis of the variants identified in this
study showed a significantly non-random distribution of the
mutations within the sequence of EDA. Fifteen separate fam-
ilies had mutations within the 7-amino acid domain (aa 153–
159) encoding two adjacent potential furin cleavage sites.
Mutations in 13 other families specifically affected the collag-
en-like domain. Ten of the families had 18 or 36 nucleotide
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in-frame deletions eliminating 2 or 4 of the (GlyXY) repeats,
and three families had missense mutations altering glycine
residues. Nine missense mutations were detected within the
TNF-like domain (aa 245–391), which is necessary and suffi-
cient for receptor binding (3, 10). In the latter class of muta-
tions, threonine 378 was altered in 4 independent families. In
addition, 6 families had nonsense or frameshift mutations al-
tering one or more of the domains cited above. Altogether, these
data strongly suggest that the predicted furin, collagen, and
TNF-like domains are essential for the function of EDA in vivo.
Finally, a single splice site mutation was detected in the cur-
rent study (IVS8 15G 3 A), which affects the donor site of
EDA-A1 but not that of EDA-A2. This mutation is predicted to
eliminate EDA-A1 only, in contrast to all other mutations that
alter both EDA-A1 and EDA-A2.
In an effort to understand the mechanism by which muta-
tions detected in families with XLHED affect the function of
EDA, we prepared a range of wild type and mutant recombi-
nant EDA proteins and analyzed them in different in vitro
assays. The mutations selected in this study are shown in bold
in Table II, and the various protein constructs are schematized
in Fig. 1B.
Binding Specificity of EDA-A1 and EDA-A2—We have pre-
viously shown the specific interaction of EDA-A1 with mouse
EDAR (10), and we now document the interaction of EDA-A1
with human EDAR (Fig. 2, A and C). Recombinant EDA always
migrated as a double band when analyzed by SDS-polyacryl-
amide gel electrophoresis, and both bands interacted with the
receptor (Fig. 2A). Peptide N-glycanase F digestion of EDA-A1
indicated that the lower and upper bands corresponded to
unglycosylated and N-glycosylated isoforms, respectively (Fig.
2B). To demonstrate the specificity of EDA/EDAR interaction,
we expressed EDAR:Fc with mutations previously detected in
two families with autosomal recessive hypohidrotic ectodermal
dysplasia (online Mendelian inheritance in man 224900) (12).
These point mutations either abolished (C87R) or strongly de-
creased (R89H) EDAR binding to EDA-A1. In addition, EDAR
C87R was recovered in poor yield, suggesting folding or solu-
bility defects (Fig. 2A). In agreement with recently published
data (3), we found that the splice variant EDA-A2 interacted
with a distinct receptor, XEDAR, and that XEDAR interacted
only with EDA-A2 among 17 ligands of the TNF family tested
(Fig. 2C).
Mutations in the TNF Homology Domain Affect Receptor
Binding—Most of the selected EDA-A1 and EDA-A2 mutants
affecting the TNF homology domain could be expressed as
soluble, FLAG-tagged secreted proteins, but mutant A356D
was entirely retained inside the cells, suggesting that it expe-
rienced folding or solubility problems (Fig. 3, A and B). Inter-
estingly, the glycosylation pattern of the mutant S374R was
indistinguishable from that of the wild type protein, although
this mutation abolishes one of the two predicted N-glycosyla-
tion sites within the TNF-like domain (Fig. 2B). We deduce
that N-glycosylation of EDA occurs on Asn313, whereas Asn372
remains unglycosylated. All mutants lost their ability to inter-
act with EDAR and XEDAR, in sharp contrast with the wild
type proteins. The only exception was EDA-A1 S374R, which
displayed weak and variable but apparently specific binding to
EDAR (Fig. 3A). Surprisingly, only the unglycosylated isoform
of this mutant interacted with the receptor.
In order to assess whether the mutations affected the qua-
ternary structure of EDA, the size of the recombinant proteins
was estimated by gel permeation chromatography (Fig. 4). Wild
type EDA and the mutant Y343C eluted with an apparent mass
of about 70-kDa, which is compatible with the predicted trim-
eric structure (Fig. 4). Mutants H252L and S374R displayed
dissociation of the glycosylated and unglycosylated subunits,
and the latter mutant had the propensity to elute as high
molecular weight complexes. EDA-A1 T378M was poorly ex-
pressed and eluted apparently as high molecular weight aggre-
gates, whereas EDA-A2 T378M was readily secreted and mi-
grated with an apparent molecular weight smaller than that of
the wild type protein. Taken together, the results indicate that,
although the impact of the various mutations on the structure
of EDA is different, they all affect interactions of EDA with
both EDAR and XEDAR.
The Collagen Domain Induces Multimerization of EDA Tri-
mers—Soluble, FLAG-tagged recombinant EDA with and with-
out the collagen domain (EDA Ser160 and EDA Glu245) and a
deletion mutant lacking four of the GlyXY repeats (EDA Ser160
D185–196) all bound EDAR equally well (Fig. 5A). The collagen
domain therefore appears not to play a direct role in receptor
binding. In related proteins with collagen domains, such as
C1q, collagen triple helices form a bundle, therefore assembling
several globular trimeric heads into a single bouquet-like struc-
ture (17). In order to test whether the collagen region of EDA
multimerizes, we generated EDA:FasL fusion proteins. We
have shown previously that the TNF family member FasL is
not cytotoxic as a soluble trimer, unless trimers are multimer-
ized by means of cross-linking antibodies (here an anti-FLAG
tag antibody) (16) (Fig. 5C, upper left panel). When FasL was
fused to the collagen domain of EDA (amino acids Ser160–
Gly242), its cytotoxic activity was increased by more than 100-
fold, indicating that ligand multimerization had likely oc-
curred. A similar effect was obtained with the collagen domain
of EDA D185–196 and EDA D218–223, suggesting that these
deletions did not affect multimerization. In contrast, no such
aggregation effect was observed when the first half of the
collagen domain was deleted (EDA Gly210) or when the point
mutation G207R was introduced (Fig. 5C).Taken together,
these results indicate that the collagen triple helix of EDA
forms multimers that are apparently not affected by in frame
deletions but can be disrupted by point mutations.
Mutations in the Furin Cleavage Site Impair Proteolytic
Processing at Arg159—Mutation of Arg residues in the pre-
dicted furin cleavage sites is a common cause of XLHED,
strongly suggesting that proteolytic processing of EDA at this
site is necessary for its function in vivo (Table II). A soluble
TABLE I
Primer pairs used for mutation detection in ED1
Exon Forward primer (59–39) Reverse primer (59–39) Ampliconsize
Restriction




1 GTCGGCCGGGACCTCCTC GCCGCCGCCCCTACTAGG 686 PstI, TaqI 135, 147, 159, 245 396 66
3 ATGTTGGCTATGACTGAGTGG CCCTACCAAGAAGGTAGTTC 248 106 57
4 GATCCCTCCTAGTGACTATC CAGACAGACAATGCTGAAAGA 215 23 57
5 AAAAAAGTAACACTGAATCCTATT CTCTCAGGATCACCCACTC 287 HinfI 101, 146, 172 180 56
6 GGAAGTCAAAAGATTATGCCC CTACCCAGGAAGAGAGCAAT 113 35 57
7 CTGAGCAAGCAGCCATTACT GGGGAGAAGCTCCTCTTTG 156 52 57
8 ACTGAGTGACTGCCTTCTCT GCACCGGATCTGCATTCTGG 214 131 57
9 TGTCAATTCACCACAGGGAG CACAGCAGCACTTAGAGG 410 PstI 141, 269 252 60
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form of EDA containing the entire extracellular domain with a
N-terminal FLAG tag (EDA Ser66) was expressed in 293T cells.
As expected, this protein was processed very efficiently, and a
small 12-kDa N-terminal fragment bearing the FLAG tag was
recovered in cell supernatants instead of the full-length 40-kDa
protein. In contrast to the 12-kDa fragment, the untagged
C-terminal fragment of EDA was readily recovered by affinity
purification on the immobilized receptor and detected by West-
ern blot using anti-EDA antibodies (Fig. 6A). N-terminal se-
quencing of purified processed EDA yielded the sequence
SKSNEGADGPVKNKK (Ser160–Lys174), demonstrating that
proteolytic cleavage occurred after Arg159. When expressed in
293T cells, mutation R153C did not prevent proteolytic proc-
essing of EDA, which still occurred after Arg159. However,
partial inhibition of the processing was observed when EDA
R153C was expressed in CHO cells (Fig. 6A). Mutation R156C,
which affects both predicted furin recognition sequences, had a
more drastic effect and entirely prevented the degradation of
EDA and loss of the FLAG tag in both cell lines (Fig. 6A).
Interestingly, the unprocessed portion of wt and mutant EDA
TABLE II
EDA mutations in XLHED
Bold, selected for further studies.




1 46insC FS FS18 1 1 (25)
1 60–61ins8 FS FS 20 1 1 (1)
1 121–122insC FS FS 41 1 1 (25)
1 C67 3 T Nonsense Q23X 1 1 (14)
Transmembrane domain (41–63)
1 C160 3 T Missense H54Y 1 1 (26)
1 C164 3 G Missense L55R 1 1 (27)
1 T181 3 C Missense Y61H 1 1 (25)
1 C183 3 G Nonsense Y61X 1 1 (28)
Extracellular domain (64–391)
1 G187 3 A Missense E63K 1 1 (14)
1 G206 3 T Missense R69L 2 2 (25)
1 252delT FS FS85 3 3 (25, 14)
1 C382 3 T Nonsense Q128X 1 1
1 C394 3 T Nonsense Q132X 1 1 (25)
Furin subdomain (150–159)
3 C457 3 T Missense R153C 4 4
3 C463 3 T Missense R155C 1 1 2 (2)
3 C466 3 A Missense R156S 1 1 (29)
3 C466 3 T Missense R156C 4 2 6 (1, 2)
3 G467 3 A Missense R156H 5a 1 6 (2)
3 A474 3 T Missense K158N 1 1
Collagen subdomain (180–235)
5 546–581 del36 Deletion In-frame 183–194del (GlyXY)34 1 1
5 553–588 del36 Deletion In-frame 185–196del (GlyXY)34 5a 2 7 (1, 2)
5 562–589 del28 Deletion 188–197del, FS198 1 1 (2)
5 G566 3 A Missense G189E 1 1
5 572–589 del18 Deletion In-frame 191–196del (GlyXY)32 3a 1 4 (1)
5 595–613 del19 Deletion 199–204del, FS205 1 1
5 599–600insC FS FS 201 1 1 (1)
5 G619 3 A Missense G207R 1 1
5 C626 3 T Missense P209L 1 1 (2)
5 G653 3 A Missense G218D 1 1
5 656–673 del18 Deletion In-frame 218–223del (GlyXY) 32 1 1
5 659–676 del18 Deletion In-frame 220–225del (GlyXY) 32 1 1 (1)
5 663–697 del35 Deletion 221–233del, FS234 1a 1 2 (2)
5 G671 3 C Missense G224A 1 1 (2)
IVS5 A 3 G at
706–2
Splice Altered splicing 1 1 (1)
6 C730 3 T Nonsense R244X 1a 1
TNF homology subdomain (250–391)
7 A755 3 T Missense H252L 1 1 (2)
7 C766 3 T Nonsense Q256X 1 1
8 G822 3 A Nonsense W274X 1 1
8 G871 3 T Missense G291W 1 1 (1)
8 G871 3 A Missense G291R 2a 1 3 (1)
8 G892 3 C Missense D298H 1 1 (1)
8 G895 3 A Missense G299S 1 3 4 (1, 2)
IVS8 G15 3 A Splice Altered splicing 1 1
9 A959 3 G Missense Y320C 1 1
9 G961 3 T Nonsense E321X 1 1 (2)
9 A1028 3 G Missense Y343C 1 1 (30)
9 G1045 3 A Missense A349T 2 2 (2)
9 G1067 3 A Missense A356D 1 1 (2)
9 G1070 3 C Missense R357P 1 1 (2)
9 C1122 3 A Missense S374R 1 1
9 A1132 3 C Missense T378P 1 1
9 C1133 3 T Missense T378M 3a 3
Totals 44 42 86
a Mutations were demonstrated to have occurred de novo.
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FIG. 1. Sequence alignment and features of EDA and EDA constructs. A, sequence alignment of EDA and of its closest relatives in the TNF
family. The transmembrane domain, furin recognition sequences, collagen domain, and b-sheets A–H of the TNF homology domain are indicated
(bold lines). The starting position (Ser66, Ser160, Gly210, and Glu245) of the various recombinant proteins is shown by an arrow, and the various
mutations studied are also indicated. Potential N-glycosylation sites are boxed. Amino acids Val307 and Glu308 are absent in EDA-A2, but
numbering of mutations in EDA-A1 and EDA-A2 is conserved for clarity. B, schematic representation of expression constructs for soluble EDA. F 5
FLAG tag plus a linker of 10 amino acids. Point mutations are indicated by an asterisk. In FasL fusion molecules, the TNF homology domain of
EDA was replaced by that of FasL.
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were clearly distinguishable following SDS-polyacrylamide gel
electrophoresis under non-reducing conditions, with a propor-
tion of the mutants R153C and R156C migrating as disulfide-
linked dimers (Fig. 6B). In summary, the results indicate that
cleavage of EDA occurs at Arg159, which corresponds to a pre-
dicted furin cleavage site, and that mutations within the furin
recognition sequence affect the cleavage to various extents.
DISCUSSION
In this study, mutations in the EDA gene were detected in
63% of the families with XLHED, which is lower than the 95%
rate we found previously (2) by the direct sequencing of affected
males. The lower detection rate is the consequence of two
factors. The use of a single set of conditions lowers the sensi-
tivity of SSCP analysis, as only 11 of the 15 known mutations
run as controls could be detected under these conditions (73%).
In addition, this study included 28% of families with “affected”
females only, which was not the case in our previous study.
Indeed, the detection rate was lower in families with female
probands (45%), and this may well be due to genetic heteroge-
neity for autosomal forms of HED.
A number of point mutations are located within the TNF
homology domain of EDA, but only one of them (Y343C) affects
a residue which, based on structural homology with known
ligand-receptor structures (4, 5), is predicted to interact with
the receptor. Indeed, this mutation abolished receptor binding
without affecting the trimeric structure of EDA, although we
cannot exclude indirect conformational effects. All other muta-
tions are predicted to have indirect effect on receptor binding,
e.g. by altering the folding of EDA. It is noteworthy that four
independent mutations (G291W, G291R, A356D, R357P) oc-
curred in two short loops at the bottom of EDA (loops BC and
FG, see Fig. 1A). The affected amino acids are probably crucial
for proper folding of the monomer, as mutation A356D resulted
in insoluble EDA-A1 and EDA-A2. Another group of mutations
(H252L, S374R) seems to affect the stability of the trimer,
because the resulting proteins contain a proportion of mono-
mers. The propensity of unglycosylated subunits to form larger
aggregates support the idea that glycosylation of some TNF
family members promotes their solubility (18). Interestingly,
one of the mutations (S374R) destroys a potential N-glycosyla-
tion site without affecting the glycosylation of EDA, suggesting
that this particular site is not recognized by the N-glycosyl-
transferase. A single mutant (S374R) retained some binding
activity to EDAR. Although preferential binding of the ungly-
cosylated (and most probably aggregated) isoform was ob-
served, the interaction appeared specific, suggesting that re-
sidual activity may be associated with this mutation in vivo. In
general, no apparent phenotype/genotype correlation was ob-
served, but the family with missense mutation S374R had two
affected males and an affected maternal grandfather with iso-
lated hypodontia. Whether residual activity of this mutant may
account for the milder phenotype, and whether there is truly a
tissue-specific difference in the function of this mutant protein
remains to be determined. Finally, one mutation (T378M) af-
fected secretion and aggregation of EDA-A1 and EDA-A2 in a
strikingly different manner. The structural reason for this dif-
ferential behavior is unclear. In summary, all missense muta-
FIG. 2. Characterization of EDA-A1/EDAR and EDA-A2/XEDAR
interactions. A, soluble recombinant EDA-A1 was immunoprecipi-
tated (IP) with EDAR:Fc fusion protein (wt or with the indicated mu-
tations) and analyzed by Western blot (WB) using anti-FLAG antibody.
Precipitated EDAR:Fc is shown in the top panel. B, deglycosylation of
EDA-A1. EDA-A1s (wt or S374R mutant) were treated 6 peptide N-
glycanase F (PNGaseF) and analyzed by Western blot with anti-FLAG
antibody. C, receptor binding ELISA. XEDAR:Fc, EDAR:Fc, and vari-
ous control receptors:Fc were captured on an ELISA plate. FLAG-EDA-
A1, FLAG-EDA-A2, and various control FLAG ligands were added as
indicated. Interactions were revealed using a monoclonal anti-FLAG
antibody. Fn14 is a recently described receptor for TWEAK (31).
FIG. 3. Expression and receptor binding of wild type and mu-
tated forms of EDA-A1 and EDA-A2. A, binding of wt and mutant
EDA-A1 to EDAR. Supernatants and cell extracts of transfected cells
are shown in the top two panels. Ligands in supernatants were immu-
noprecipitated (IP) with EDAR:Fc and analyzed by Western blot (WB)
in the 3rd panel. Precipitated EDAR:Fc is shown in the bottom panel.
Results of the immunoprecipitation with a control receptor (Fas:Fc) is
shown for EDA-A1 wt and S374R. B, binding of wt and mutant EDA-A2
to XEDAR. Analysis was performed essentially as in B, except that
EDA-A2 and XEDAR were used.
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tions in the TNF homology domain result in abolished or much
impaired binding of EDA-A1 to EDAR and EDA-A2 to XEDAR.
A number of mutations occurring outside the TNF homology
domain did not affect binding to the receptor in an in vitro
assay, indicating that the interaction of EDA with its recep-
tor(s) is necessary but not sufficient for its function in vivo. In
particular, the integrity of the collagen domain appears to be
functionally essential, and we provided evidence that it may
serve to multimerize EDA trimers. This is in strong support of
the hypothesis that EDA belongs to the C1q as well as to the
TNF family of proteins (19). C1q family members are charac-
terized by the presence of a C-terminal globular trimeric do-
main, with striking structural homology to TNF (20), which is
prolonged by a collagen triple helix further assembling into an
N-terminal bundle structure, giving rise to a highly multimeric
superstructure. In the TNF family, it has been shown that the
activity of soluble trimers can be dramatically increased by
antibody-mediated multimerization, thereby mimicking the
membrane-bound form of the ligand (16, 21). A highly multim-
eric structure of EDA would provide a powerful means for the
soluble protein to signal through high valency receptor cluster-
ing. In line with this hypothesis, we found that a naturally
occurring point mutation (G207R) in the collagen domain com-
pletely abolished the bundle effect. It is, however, likely that
the collagen domain also serves additional functions; a number
of families with XLHED displayed in frame deletion of 2 or 4
GlyXY repeats in the predicted bundle domain of the collagen
triple helix, i.e. before the interruption in the GlyXY repeats.
Deletions of 2 GlyXY repeats can also be found C-terminal to
the interruption. Surprisingly, the activity of recombinant pro-
teins containing these types of deletions was indistinguishable
from wild type, at least in the model systems utilized. The
deletions may specifically affect multimerization of the colla-
gen domain under in vivo conditions. Alternatively, the colla-
gen domain may have additional functions, e.g. interaction
with other proteins. It is well known for C1q that the collagen
domain interacts with the serine proteases C1r and C1s to form
C1, the first component of the serum complement system, and
with a number of other proteins, including membrane-bound
receptors (22). Further investigations are required to under-
FIG. 4. Gel filtration analysis of mu-
tated EDA-A1 and EDA-A2. wt and mu-
tant EDA-A1 Glu245 (left panels) and
EDA-A2 Glu245 (right panels) were loaded
onto a Superdex-200 column and eluted in
phosphate-buffered saline. Fractions (700
ml) were precipitated and analyzed by an-
ti-FLAG Western blot. The top panel
shows Ponceau S staining of the co-in-
jected internal standards catalase and
ovalbumin.
FIG. 5. Effect of the collagen do-
main on the receptor activity of
EDA-A1 and on the cytotoxic activity
of FasL. A, EDA-A1, with or without wild
type or mutated collagen domain, was im-
munoprecipitated (IP) with EDAR:Fc and
analyzed by Western blot (WB) as indi-
cated. B, FasL and the various EDA:FasL
fusion proteins were immunoprecipitated
with Fas:Fc and analyzed by Western
blot. C, cytotoxic activity of FasL and of
the various EDA:FasL fusion proteins
was monitored on Jurkat cells, in the
presence (black squares) or in the absence
(open squares) of cross-linking anti-FLAG
antibody. Cytotoxic activity in the ab-
sence of anti-FLAG reveals oligomeriza-
tion of FasL trimers by the collagen do-
main of EDA.
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stand the molecular mechanism underlying loss of function of
EDA in these particular deletion mutants.
15 families with XLHED displayed 5 distinct mutations in
the furin consensus recognition sequences of EDA, demonstrat-
ing an important functional role for this 7-aa sequence. The
release of soluble EDA upon proteolytic processing is an ex-
pected event, as mRNAs for EDA and EDAR are not expressed
in adjacent cells but rather in spatially distinct tissues, at least
in the developing tooth (10). EDA contains two overlapping
furin recognition sequences (RVRR and RNKR spanning aa
153–156 and 156–159, respectively). Because Arg156 is part of
both sequences, it is hardly surprising that mutation R156C
completely abolished EDA processing. Mutation R153C also
affected the cleavage of EDA, but in a less dramatic manner.
Although this mutation destroys only one of the two furin sites,
this must be sufficiently disturbing to prevent efficient release
of EDA from the cells naturally expressing it. These cells may
express low amounts of furin or furin isoforms whose specificity
may extend further than the canonical tetrapeptide recognition
sequence. However, as mutations affecting the first furin do-
main invariably yield Cys residues, and as these Cys residues
appear to form novel disulfide bridges, it is possible that this
novel structural constraint prevents proper recognition of the
remaining intact furin site. It also clearly appears from this
study that, beside the furin cleavage sites, there are no alter-
native sites for solubilization of EDA. In particular, the se-
quence RRER (aa 69–72) and the basic motives KNKK and
KGKK (aa 171–174 and 175–178) were not cleaved in our
expression system. The latter two motifs are encoded in the
small exon 4 and are also found in the sequences of Tweak and
APRIL. However, mutations in these sequences have not been
described so far in association with XLHED.
A single splice site mutation was detected in the current
study (IVS8 G15 3 A), which affects the splice donor site of
exon 8 utilized to generate the 391-aa EDA-A1 isoform of the
ligand. EDA-A2 utilizes an alternate splice site 6 base pairs 59
to this site. This mutation probably interferes with splicing of
EDA-A1 but not EDA-A2, as computer analysis by HSPL (pre-
diction of splice sites in human DNA sequence) demonstrates a
complete loss of the A1 but not of the A2 donor site. This
together with the fact that genetic defects in EDA and in EDAR
both lead to identical phenotypes indicate a crucial role for
EDA-A1/EDAR interactions during morphogenesis. The role of
the parallel EDA-A2/XEDAR interaction is less well estab-
lished. If at all involved in hair, sweat gland, and teeth forma-
tion, it is not able to rescue a genetic deficiency in EDAR. In
addition, there is no evidence to date for mutations in XEDAR
being associated with the HED phenotype. XEDAR may play a
distinct role in skin development, which does not translate into
an HED phenotype upon dysfunction. Alternatively, inactiva-
tion of XEDAR might be lethal, but this would only be possible
if it binds another ligand beside EDA-A2 or fulfills a vital,
ligand-independent function. TROY/TAJ is a close sequence
homologue of XEDAR, which is also expressed in the develop-
ing skin (23, 24). The precise functional roles of XEDAR and
TROY and their interplay with the EDAR pathway remain to
be determined.
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